Tissue Diagnostics Market Size was valued at USD 5.4 Billion in 2023. The tissue diagnostics market industry is projected to grow from USD 6.1 Billion in 2024 to USD 14.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.50% during the forecast period (2024 - 2032). The tissue diagnostics market is anticipated to experience growth throughout the forecast period due to significant market drivers, such as the rising incidence of various cancer types, including breast and lung cancer.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for tissue diagnostics is expanding as a result of the growing incidence of cancer in developed nations. Cancer is a complex illness that develops over time as a result of numerous carcinogenesis processes, including trials. Therefore, there are several challenges associated with a cancer diagnosis, treatment plan, and outlook. On the other hand, cancer ranks among the leading causes of death worldwide. The World Health Organization reports that cancer claimed the lives of over 10 million people in 2020. However, the death rate can be decreased if the cancer is discovered at an early stage. Therefore, tissue diagnosis treatment—a procedure that aids in the discovery of several biomarkers and proteins that aid in the identification of cancer—is used for cancer screening and early detection. Among the often-used cancer diagnostic procedures are endoscopy, imaging, biopsy, genetic testing, and laboratory testing. The market CAGR is growing as more tissue diagnostic tests are available.
Effective diagnostic methods are desperately needed as the illness burden continues to rise as a result of aging populations and changing lifestyles. This increase in demand highlights how crucial early identification is to the effectiveness of treatment results, as evidenced by the size of the cancer market. Accurately classifying cancer kinds and directing treatment choices are greatly aided by tissue diagnostics, which uses methods including biopsies and molecular testing. For instance, in order to diagnose cancer in its early stages, GRAIL has started non-invasive blood tests that examine circulating tumor DNA. This innovative technique demonstrates the vital role tissue diagnostics plays in raising the incidence of cancer and enhancing the effectiveness of treatment. Consequently, in order to keep up with the growing demand for healthcare across the globe, the tissue diagnostics market is continuing to grow quickly.
The increasing need for personalized medicine can be attributed to the progress made in genetic and molecular technology, which allows for customized treatment plans based on unique patient traits. To maximize therapeutic efficacy and reduce side effects, this strategy takes into account lifestyle factors, genetic composition, and illness biomarkers. Personalized therapies with better success rates and fewer adverse effects than conventional treatments are becoming more and more sought after by patients. For instance, comprehensive genomic profiling techniques that examine tumor DNA to pinpoint particular mutations and inform treatment choices have been developed by Foundation Medicine. With the help of this method, oncologists can recommend individualized treatments based on each patient's distinct genetic profile, improving treatment results and patient satisfaction. Furthermore, the recognition of potential cost savings and enhanced patient outcomes linked to personalized medicine by healthcare providers is propelling its acceptance and propelling market growth within the healthcare sector. Thus, driving the tissue diagnostics market revenue.
The Tissue Diagnostics Market segmentation, based on product, includes Instruments and Reagents & Consumables. In 2023, the reagents & consumables segment dominated the market, which is attributed to a continuous need for consumables, increased output, and research to create novel reagents and other consumables. Sakura Finetek USA, Inc., for instance, released on October 30, 2020, a much-enlarged reagent and consumables catalog for the Tissue-Tek Genie Advanced Staining System. Because of the continuous need for consumables in research, there is a larger manufacturing demand, which is driving up market revenue growth.
The Tissue Diagnostics Market segmentation, based on technology, includes Immunohistochemistry, In-situ Hybridization, Digital Pathology and Workflow Management, and Other Technologies. The immunohistochemistry category generated the most income in 2023. Its well-established presence and inexpensive costs explain this. Furthermore, IHC can be performed on both fresh and frozen tissue samples. The origin of a tumor can be ascertained with the aid of various IHC tests. IHC is a better option because this is not achievable with other standard histology testing.
The Tissue Diagnostics Market segmentation, based on application, includes Breast Cancer, Prostate Cancer, Gastric Cancer, and Other Cancers. In 2023, the breast cancer segment dominated the market due to a rise in the global patient population for breast cancer. Furthermore, a few research initiatives in conjunction with government agencies and business organizations are anticipated to propel the creation of cutting-edge diagnostic tools for breast cancer.
Figure 1: Tissue Diagnostics Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American tissue diagnostics market area will dominate this market, considering the substantial need for cancer diagnosis supplements and the robust presence of numerous public programs targeted at lowering the occurrence of cancer. Furthermore, favorable R&D activities, expanding medical facilities, government initiatives for the creation and application of novel diagnostic platforms, and access to technically sophisticated cancer diagnostic techniques and equipment would all support regional expansion.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: TISSUE DIAGNOSTICS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe tissue diagnostics market accounts for the second-largest market share because of the rise in cancer cases and public awareness of the disease, the creation of cutting-edge technology, the size of the patient population, the increase in disposable income, the increased demand for and knowledge of advanced diagnostic techniques, and the evolution of healthcare systems. Further, the German tissue diagnostics market held the largest market share, and the UK tissue diagnostics market was the fastest growing market in the European region.
The Asia-Pacific Tissue Diagnostics Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the region's rapid population growth and rise in chronic sickness cases. Lung cancer incidence are rising as a result of less strict air pollution restrictions in growing economies like China and India. It is anticipated that this would lead to an even greater demand in laboratories and hospitals for tissue diagnostics. Moreover, China’s tissue diagnostics market held the largest market share, and the Indian tissue diagnostics market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the tissue diagnostics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the tissue diagnostics industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global tissue diagnostics industry to benefit clients and increase the market sector. In recent years, the tissue diagnostics industry has offered some of the most significant advantages to medicine. Major players in the tissue diagnostics market are attempting to increase market demand by investing in research and development operations, including Abbott Laboratories, BioGenex Laboratories, Agilent Technologies Inc., ILLUMINA Inc., Merck KGa, Danaher Corporation, F. Hoffmann-La Roche Ltd, Qiagen NV, and Thermo Fisher Scientific Inc.
Abbott Laboratories (Abbott) is a healthcare product manufacturer and distributor that specializes in the discovery, development, manufacturing, and marketing of a wide range of products, such as adult and pediatric nutritional supplements, diagnostic systems and tests, and branded generic medications. Additionally, the company sells a range of medical equipment related to heart failure, electrophysiology, rhythm control, vascular and structural cardiac devices, and neuromodulation. The business also sells dietary supplements, nutrition goods, and minerals.
A biotechnology corporation called F. Hoffmann-La Roche Ltd. (Roche) creates medications and diagnostic tools to treat serious illnesses. It offers medications to treat conditions related to the central nervous system, the ophthalmological system, cancer, other autoimmune diseases, infectious diseases, and respiratory illnesses. The company also provides diabetes management systems, tissue-based cancer diagnostics, and in vitro diagnostics. The FDA approved F. Hoffman-La Roche Ltd.'s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody in October 2022 for use as a companion diagnostic test to detect patients with metastatic breast cancer who express low levels of HER2.
Key companies in the tissue diagnostics market include
June 2023: In Marana, Roche Tissue Diagnostics is establishing a 60,000-square-foot facility next to an existing distribution center as part of its expansion into the production of cancer-detecting apparatus and tests. Relocating from Roche's main campus in Oro Valley, the new facility will contain all instrument manufacturing operations. In order to fulfill the rising demand for its products, the company is moving to enhance production capacity.
January 2023: In order to offer workflow solutions for multiplex assays in the clinical research sector and create multiplex-immunohistochemistry diagnostic solutions for tissue analysis, Agilent Technologies teamed up with Akoya Biosciences. A full end-to-end workflow for mIHC and mIF assays is to be created by integrating Agilent's Dako Omnis with Akoya's PhenoImager HT through a joint venture.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 5.4 Billion |
| Market Size 2024 | USD 6.1 Billion |
| Market Size 2032 | USD 14.8 Billion |
| Compound Annual Growth Rate (CAGR) | 13.50% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Technology, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories, BioGenex Laboratories, Agilent Technologies Inc., ILLUMINA Inc., Merck KGa, Danaher Corporation, F. Hoffmann-La Roche Ltd, Qiagen NV, and Thermo Fisher Scientific Inc |
| Key Market Opportunities | ·      Increasing the number of private diagnostic centers worldwide |
| Key Market Dynamics | ·      Global cancer incidence is rising ·      Expansion of personalized medications and diagnostics |
Frequently Asked Questions (FAQ) :
The Tissue Diagnostics Market size was valued at USD 5.4 Billion in 2023.
The global market is projected to grow at a CAGR of 13.50% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Abbott Laboratories, BioGenex Laboratories, Agilent Technologies Inc., ILLUMINA Inc., Merck KGa, Danaher Corporation, F. Hoffmann-La Roche Ltd, Qiagen NV, and Thermo Fisher Scientific Inc.
The reagents & consumables category dominated the market in 2023.
The immunohistochemistry category had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
